Drug combination extends survival by more than a year in metastatic prostate cancer

Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists. The dramatic results in a multi-center phase III trial should change the way physicians have routinely treated such patients since the 1950s, they said.